Perrigo licenses Rx brands to Medimetriks

New Jersey-based Medimetriks Pharmaceuticals has entered into a licensing agreement with fellow US firm Perrigo to acquire the US marketing rights for Centany ointment and two prescription keratolytic brands. Patented through 2018, Centany represents an important step in Medimetriks' plan to commercialize patent-protected therapies for the dermatology and podiatry markets that offer important patient benefits. The company says it plans to launch Centany in early 2009, with the two additional products following shortly thereafter.

Previously marketed by Johnson & Johnson's OrthoNeutrogena professional division, Centany is indicated for the topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150.0 million. Centany received a New Drug Approval in December of 2002 based in part on the unique properties of its vehicle, which offers important benefits over its competitors, the company claims.